Abbisko Cayman Limited (2256.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
Building 3, No. 898
Shanghai, SH 201203
China
Phone
86 21 6891 2098
Website
Sector
Healthcare
Industry
Biotechnology
Employees
281
First IPO Date
October 13, 2021
| Name | Title | Pay | Year Born |
| Yao-Chang Xu | Founder, Chairman of the Board & Chief Executive Officer | 5.04M | 1957 |
| Hongping Yu | Co-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director | 3.41M | 1968 |
| Jing Ji | Chief Medical Officer & Executive Director | 5.74M | 1970 |
| Zidong Zhang | Group Chief Financial Officer | 0 | 1981 |
| Zhen Zhang | Senior VP of CMC & Head of Chemistry, Manufacturing and Controls | 0 | 1973 |
| Hanxi Zhang | Joint Company Secretary | 0 | N/A |
| Jia Feng | Vice President of HR and Operations & Head of Human Resource | 0 | N/A |
| Yongyi Li | General Counsel | 0 | 1976 |
| Sio Ngo Lin | Joint Company Secretary | 0 | N/A |
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.